Healthy Adult MaleNCT07217210
Multi-Ingredient Preworkout Supplement on Peak Torque and Muscle Activation During Fatigue
A study testing Multi-ingredient preworkout supplement in people with Healthy Adult Male, run by Northern Illinois University at 1 site in United States.
Trial summary
The primary purpose of the present study was to examine the acute effects of a MIPS product on peak torque production of the leg extensors during a fatiguing isokinetic protocol involving isometric, concentric, and eccentric muscle actions. Read more about this study
- Who is it for?
- Ages 19 to 29 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult Male
- What is being tested?
- Multi-ingredient preworkout supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 13 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Nov 2021to 1 Apr 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 29 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male, 19-29 years of age, one year of resistance training experience
Who cannot join
- Subjects were eligible to participate if they did not report: 1) cardiovascular disease, metabolic, renal, hepatic, or musculoskeletal disorders; 2) use of any medications; 3) use of nutritional supplements; 4) habitual use of caffeine (≥ 1 caffeinated beverage per day); or 5) participation in another clinical trial or investigation of another nutritional product within 30 days of screening/enrollment.
Trial locations and contacts
1 site in 1 country.
United States1 site
Northern Illinois University
DeKalb, Illinois, 60115
About this study
Official title: Acute Effects of a Multi-Ingredient Preworkout Supplement on Peak Torque and Muscle Activation During an Isokinetic Fatigue Protocol
The primary purpose of the present study was to examine the acute effects of a MIPS product on peak torque production of the leg extensors during a fatiguing isokinetic protocol involving isometric, concentric, and eccentric muscle actions. In addition, we investigated the effects of the MIPS supplement on EMG amplitude and median power frequency (MDF) responses from the vastus lateralis, rectus femoris, and vastus medi-alis muscles.
Read the detailed description
In the past several years, the use of multi-ingredient pre-workout supplements (MIPS) has become extremely popularized, and their ergogenic potential has become well-established for various sports and within the general population by both competi-tive and recreational athletes [1-6]. Some of the more prevalent ingredients in MIPS in-clude caffeine, β-alanine, L-citrulline, L-arginine, and creatine, with many of these in-gredients and others often combined into proprietary blends [7]. Although recent find-ings indicate synergistic effects among these ingredients may be present [8], it has been suggested that caffeine is the predominant factor responsible for the acute ergogenic effects associated with MIPS [2,9]. In fact, the recommended timing for ingestion of most MIPS is likely based on the stimulating effects of caffeine which typically peaks in the bloodstream 30-60 minutes post-ingestion [10,11]. As a nutritional supplement, caffeine has been shown to be beneficial for maintaining maximal strength and endur-ance as well as improving time-trial performance and other forms of high-intensity ex-ercise [10,11]. These effects have been attributed to improved motor unit firing rates and calcium release from the sarcoplasmic reticulum, subsequently enhancing muscle contraction force [4,12]. β-alanine is another ingredient included in most MIPS [7] and has been identified as the rate-limiting precursor to carnosine, an intracellular muscle buffer [13]. Supplementation with β-alanine has been shown to increase intramuscular levels of carnosine, thereby attenuating metabolic acidosis during high-intensity exer-cise [13]. As precursors to the potent vasodilator, nitric oxide, both L-citrulline and L-arginine supplements have been demonstrated to enhance blood flow to active mus-cles, subsequently delaying the onset of muscular fatigue [14-16]. Based on these collec-tive physiological mechanisms, a MIPS containing these notable ergogenic ingredients (caffeine, β-alanine, L-citrulline, L-arginine) may provide neuromuscular benefits for sustaining force or power output during various forms of vigorous activity.
The vast majority of previous investigations examining the acute effects of MIPS on performance have focused on isotonic variables of upper and lower body muscular strength [i.e. bench press, leg press, and squat one-repetition maximum (1-RM), maxi-mum voluntary contractions (MVC)], endurance (i.e. repetitions to failure at %1-RM), and power (vertical jump, Wingate Anaerobic testing, and critical power) [1-6,9,12,18,19]. Despite conflicting evidence for maximal force and power production [4,6,20,21], the findings of several studies [1,3,4,12,17-19,22,23] have largely indicated acute MIPS supplementation can enhance overall force retention and muscular endur-ance during prolonged or intermittent bouts of high intensity activity. Currently, how-ever, the exact underlying mechanisms responsible for these benefits on neuromuscular function are poorly understood.
Isokinetic dynamometers coupled with surface electromyography (EMG) record-ings are two frequently utilized instruments for the non-invasive assessment of neu-romuscular function and fatigue during static and dynamic muscle actions [24-27]. The utility of isokinetic testing involves the ability to measure isometric, concentric, and eccentric torque levels across an entire range of motion at controlled velocities with minimal skill involvement required. Results from isokinetic testing can provide torque production at different joint angles, while identifying muscle imbalances, tracking the recovery process from injury or surgery, and measuring the rate of force development [28,29]. Thus, as both a training and assessment tool, isokinetic testing is common in clinical and performance settings.
Surface electromyography (EMG) is a technique that involves recording and quantifying the action potentials associated with contracting skeletal muscle fibers [30]. The amplitude contents of the EMG signal reflect the level of muscle activation (i.e. motor unit recruitment and firing rates) [31], whereas the frequency contents pro-vide information related to the muscle fiber conduction velocity [32]. To our knowledge, only one study [5] has directly examined EMG responses associated with acute MIPS administration. Specifically, Negro et al. [5] reported acute MIPS (creatine, arginine, β-alanine, glutamine, taurine) ingestion improved EMG-based indicators of fatigue (i.e. conduction velocity, fractal dimension) during sustained isometric contrac-tions following a resistance exercise protocol designed to elicit fatigue. The authors [5] proposed these acute benefits of their MIPS product may be attributable to improved: 1) peripheral components of performance fatiguability, 2) buffering capacity of the mus-cle from β-alanine, and 3) regulation of mechanisms associated with exercise-induced fatigue from arginine, glutamine, and taurine. Based on these findings [5], valuable in-sight can be gained into the underlying neuromuscular factors associated with MIPS ingestion by examining muscle function and fatigue through isokinetic and EMG as-sessments. Thus, the primary purpose of the present study was to examine the acute ef-fects of a MIPS product on peak torque production of the leg extensors during a fatigu-ing isokinetic protocol involving isometric, concentric, and eccentric muscle actions. In addition, we investigated the effects of the MIPS supplement on EMG amplitude and median power frequency (MDF) responses from the vastus lateralis, rectus femoris, and vastus medialis muscles.
- Conditions
- Healthy Adult Male
- Being tested
- Multi-ingredient preworkout supplement
- Keywords
- isometric; concentric; eccentric; leg extensors; quadriceps; electromyography
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-ingredient preworkout supplementDietary supplement
Experimental supplement.
| Study group | Role | What they receive |
|---|---|---|
| Supplement group | Experimental | Multi-ingredient preworkout supplement Receives: Dietary Supplement: Multi-ingredient preworkout supplement |
| Placebo group | Placebo comparator | Microcystalline cellulose Receives: Dietary Supplement: Multi-ingredient preworkout supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak torque
Isometric, concentric, and eccentric.
Measured: Two days.
Secondary outcomes (1)
EMG responses.
Relative amplitude and median power frequency.
Measured: 60 minutes per visit over the course of two visits (each separated by one week).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2025
- Study start15 Nov 2021
- Primary completion1 Mar 2022
- Study completion1 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Adult MaleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Within-subjects, placebo-controlled, crossover design
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northern Illinois University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Clayton Camic, PHD, Principal investigator, Northern Illinois University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07217210
- Sponsor's protocol ID
- #HS22-0139
- Status last verified
- Oct 2025
- First submitted
- 13 Oct 2025
- Last updated
- 15 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The informed consent and IRB application indicated that individual data would not be shared.
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Effects of a Multi-Ingredient Preworkout Supplement on Peak Torque and Muscle Activation During an Isokinetic Fatigue Protocol
- ClinicalTrials.gov ID
- NCT07217210
- Acronym / sponsor ID
- #HS22-0139
- Conditions
- Healthy Adult Male
- Keywords
- isometric; concentric; eccentric; leg extensors; quadriceps; electromyography
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Northern Illinois UniversityUniversity, hospital or other
- Study start
- 15 Nov 2021 (actual)
- Primary completion
- 1 Mar 2022 (actual)
- Study completion
- 1 Apr 2022 (actual)
- First posted
- 15 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of the present study was to examine the acute effects of a MIPS product on peak torque production of the leg extensors during a fatiguing isokinetic protocol involving isometric, concentric, and eccentric muscle actions. In addition, we investigated the effects of the MIPS supplement on EMG amplitude and median power frequency (MDF) responses from the vastus lateralis, rectus femoris, and vastus medi-alis muscles.
Detailed description
In the past several years, the use of multi-ingredient pre-workout supplements (MIPS) has become extremely popularized, and their ergogenic potential has become well-established for various sports and within the general population by both competi-tive and recreational athletes [1-6]. Some of the more prevalent ingredients in MIPS in-clude caffeine, β-alanine, L-citrulline, L-arginine, and creatine, with many of these in-gredients and others often combined into proprietary blends [7]. Although recent find-ings indicate synergistic effects among these ingredients may be present [8], it has been suggested that caffeine is the predominant factor responsible for the acute ergogenic effects associated with MIPS [2,9]. In fact, the recommended timing for ingestion of most MIPS is likely based on the stimulating effects of caffeine which typically peaks in the bloodstream 30-60 minutes post-ingestion [10,11]. As a nutritional supplement, caffeine has been shown to be beneficial for maintaining maximal strength and endur-ance as well as improving time-trial performance and other forms of high-intensity ex-ercise [10,11]. These effects have been attributed to improved motor unit firing rates and calcium release from the sarcoplasmic reticulum, subsequently enhancing muscle contraction force [4,12]. β-alanine is another ingredient included in most MIPS [7] and has been identified as the rate-limiting precursor to carnosine, an intracellular muscle buffer [13]. Supplementation with β-alanine has been shown to increase intramuscular levels of carnosine, thereby attenuating metabolic acidosis during high-intensity exer-cise [13]. As precursors to the potent vasodilator, nitric oxide, both L-citrulline and L-arginine supplements have been demonstrated to enhance blood flow to active mus-cles, subsequently delaying the onset of muscular fatigue [14-16]. Based on these collec-tive physiological mechanisms, a MIPS containing these notable ergogenic ingredients (caffeine, β-alanine, L-citrulline, L-arginine) may provide neuromuscular benefits for sustaining force or power output during various forms of vigorous activity.
The vast majority of previous investigations examining the acute effects of MIPS on performance have focused on isotonic variables of upper and lower body muscular strength [i.e. bench press, leg press, and squat one-repetition maximum (1-RM), maxi-mum voluntary contractions (MVC)], endurance (i.e. repetitions to failure at %1-RM), and power (vertical jump, Wingate Anaerobic testing, and critical power) [1-6,9,12,18,19]. Despite conflicting evidence for maximal force and power production [4,6,20,21], the findings of several studies [1,3,4,12,17-19,22,23] have largely indicated acute MIPS supplementation can enhance overall force retention and muscular endur-ance during prolonged or intermittent bouts of high intensity activity. Currently, how-ever, the exact underlying mechanisms responsible for these benefits on neuromuscular function are poorly understood.
Isokinetic dynamometers coupled with surface electromyography (EMG) record-ings are two frequently utilized instruments for the non-invasive assessment of neu-romuscular function and fatigue during static and dynamic muscle actions [24-27]. The utility of isokinetic testing involves the ability to measure isometric, concentric, and eccentric torque levels across an entire range of motion at controlled velocities with minimal skill involvement required. Results from isokinetic testing can provide torque production at different joint angles, while identifying muscle imbalances, tracking the recovery process from injury or surgery, and measuring the rate of force development [28,29]. Thus, as both a training and assessment tool, isokinetic testing is common in clinical and performance settings.
Surface electromyography (EMG) is a technique that involves recording and quantifying the action potentials associated with contracting skeletal muscle fibers [30]. The amplitude contents of the EMG signal reflect the level of muscle activation (i.e. motor unit recruitment and firing rates) [31], whereas the frequency contents pro-vide information related to the muscle fiber conduction velocity [32]. To our knowledge, only one study [5] has directly examined EMG responses associated with acute MIPS administration. Specifically, Negro et al. [5] reported acute MIPS (creatine, arginine, β-alanine, glutamine, taurine) ingestion improved EMG-based indicators of fatigue (i.e. conduction velocity, fractal dimension) during sustained isometric contrac-tions following a resistance exercise protocol designed to elicit fatigue. The authors [5] proposed these acute benefits of their MIPS product may be attributable to improved: 1) peripheral components of performance fatiguability, 2) buffering capacity of the mus-cle from β-alanine, and 3) regulation of mechanisms associated with exercise-induced fatigue from arginine, glutamine, and taurine. Based on these findings [5], valuable in-sight can be gained into the underlying neuromuscular factors associated with MIPS ingestion by examining muscle function and fatigue through isokinetic and EMG as-sessments. Thus, the primary purpose of the present study was to examine the acute ef-fects of a MIPS product on peak torque production of the leg extensors during a fatigu-ing isokinetic protocol involving isometric, concentric, and eccentric muscle actions. In addition, we investigated the effects of the MIPS supplement on EMG amplitude and median power frequency (MDF) responses from the vastus lateralis, rectus femoris, and vastus medialis muscles.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Within-subjects, placebo-controlled, crossover design
| Arm | Type | Receives |
|---|---|---|
| Supplement group | Experimental | Dietary Supplement: Multi-ingredient preworkout supplementMulti-ingredient preworkout supplement |
| Placebo group | Placebo comparator | Dietary Supplement: Multi-ingredient preworkout supplementMicrocystalline cellulose |
Who may qualify
- Ages
- 19 to 29 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Male, 19-29 years of age, one year of resistance training experience
Key exclusion criteria (1 listed)
- Subjects were eligible to participate if they did not report: 1) cardiovascular disease, metabolic, renal, hepatic, or musculoskeletal disorders; 2) use of any medications; 3) use of nutritional supplements; 4) habitual use of caffeine (≥ 1 caffeinated beverage per day); or 5) participation in another clinical trial or investigation of another nutritional product within 30 days of screening/enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-ingredient preworkout supplementExperimental supplement. | Dietary supplement | Placebo group, Supplement group |
Primary outcome
Peak torque
Time frame: Two days.
Isometric, concentric, and eccentric.
1 secondary outcome
EMG responses.
Time frame: 60 minutes per visit over the course of two visits (each separated by one week).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2025.
- Individual participant dataSharing planned: No. The informed consent and IRB application indicated that individual data would not be shared.
Related trials for Healthy Adult Male
Not yet recruitingPhase 1
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Adults
Focal Onset Seizure
Active, not recruitingPhase 1/2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
RecruitingPhase 1/2
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Recruiting
Pharmacokinetic (PK) Study of Phytochemicals in Whole Grains (WGs)- Brown Rice
Healthy Adult Males, Healthy Adult Females
RecruitingPhase 1
Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function
Renal Impairment, Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clayton Camic, PHD principal investigator
Northern Illinois University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multi-ingredient preworkout supplement in people with Healthy Adult Male, run by Northern Illinois University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak torque (time frame: Two days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2025.